NAFLD: What Is Fatty Liver Disease and How to Reverse It Naturally

What Is NAFLD?

Non-alcoholic fatty liver disease (NAFLD) is defined by the accumulation of excess fat (triglycerides) in liver cells in people who drink little or no alcohol. It represents a spectrum of disease:

• Simple steatosis (non-alcoholic fatty liver, NAFL): Fat accumulation without significant inflammation or scarring. Generally benign but not harmless — it increases cardiovascular disease risk even without progression.
• Non-alcoholic steatohepatitis (NASH): Fat plus liver inflammation and hepatocyte injury. NASH can progress to cirrhosis and is now the second leading cause of liver transplantation in the U.S., expected to become the first.
• Cirrhosis: Advanced scarring (fibrosis) that impairs liver function and increases hepatocellular carcinoma risk.

In 2023, leading hepatology societies updated nomenclature to "metabolic dysfunction-associated steatotic liver disease" (MASLD) to emphasize the metabolic drivers and reduce stigma — but NAFLD remains the widely recognized term clinically.

The Role of Insulin Resistance

Insulin resistance is the central driver of NAFLD. When cells become resistant to insulin's signals, the pancreas compensates with higher insulin output (hyperinsulinemia). This cascade drives NAFLD through multiple mechanisms:

• Hyperinsulinemia activates de novo lipogenesis (DNL) — the liver converts excess carbohydrates into triglycerides at an accelerated rate
• Insulin resistance in adipose tissue increases free fatty acid release from fat cells into the portal circulation, flooding the liver with lipids
• Impaired mitochondrial beta-oxidation reduces the liver's ability to burn incoming fatty acids, causing accumulation
• Hyperinsulinemia suppresses apolipoprotein B (ApoB) synthesis, reducing the liver's ability to export triglycerides via VLDL particles

This is why NAFLD is strongly associated with obesity (especially central/visceral obesity), type 2 diabetes, metabolic syndrome, and polycystic ovarian syndrome (PCOS) — all conditions driven by or causing insulin resistance. Read our guide on insulin resistance symptoms and how to reverse it for foundational context.

Who Gets NAFLD?

While obesity and type 2 diabetes dramatically increase risk, NAFLD occurs in lean individuals too ("lean NAFLD") — approximately 7% of lean adults have NAFLD, driven by visceral fat accumulation, genetic variants (especially PNPLA3 and TM6SF2), gut microbiome dysbiosis, and dietary factors independent of total caloric excess.

Risk factors include:

• Central obesity and high waist circumference
• Type 2 diabetes or prediabetes
• Metabolic syndrome (hypertension, dyslipidemia, central obesity, insulin resistance)
• High dietary fructose intake (especially from sugar-sweetened beverages)
• Sedentary lifestyle
• Obstructive sleep apnea
• Hypothyroidism
• Genetic predisposition (PNPLA3 I148M variant increases NAFLD risk 2-3 fold)

Symptoms and Diagnosis: The Silent Disease

NAFLD is largely asymptomatic in its early stages — most people discover it incidentally on abdominal ultrasound or when elevated liver enzymes (ALT, AST) are found on routine blood work. Some patients report vague right upper quadrant discomfort or fatigue in more advanced disease.

Diagnosis approaches:

• Liver ultrasound: Can detect steatosis above 30% but misses early and lean NAFLD
• Liver function tests (AST/ALT): May be normal even in significant NAFLD; ALT is more specific but lacks sensitivity
• FibroScan (transient elastography): Non-invasive assessment of liver stiffness and fat content; increasingly used for screening and monitoring
• MRI-PDFF (proton density fat fraction): Gold standard non-invasive fat quantification, detecting as little as 5% steatosis
• Liver biopsy: Gold standard for grading NASH and fibrosis stage, but invasive; reserved for cases where non-invasive tests are inconclusive

Lifestyle Interventions: The Cornerstone of Treatment

Weight Loss

Weight loss is the most evidence-based intervention for NAFLD. Data consistently shows:

• 5–7% body weight loss reduces liver fat content significantly
• 7–10% loss can resolve NASH (liver inflammation)
• ≥10% loss can reverse established fibrosis

Importantly, it's not just any weight loss — preserving muscle while losing fat is important. Crash diets can actually worsen NAFLD acutely by flooding the liver with free fatty acids from rapid adipose mobilization.

Dietary Approaches

Mediterranean diet: The most consistently evidence-supported dietary pattern for NAFLD. Rich in olive oil, vegetables, legumes, fish, and whole grains while limiting refined carbohydrates and red meat. Reduces liver fat and inflammation independently of weight loss in some studies.

Low-carbohydrate/ketogenic diets: Highly effective for rapid liver fat reduction — studies show 30–40% reduction in liver fat within 2 weeks on a ketogenic diet, primarily by suppressing de novo lipogenesis. A powerful short-to-medium-term intervention, particularly for insulin-resistant individuals.

Eliminate liquid fructose: Sugar-sweetened beverages are the single most potent dietary driver of de novo lipogenesis and NAFLD. Even in isocaloric conditions, fructose preferentially drives liver fat accumulation. Eliminating sodas, fruit juices, and sweetened beverages produces rapid improvements in liver fat.

Reduce ultra-processed foods: Independent of caloric content, ultra-processed food consumption is associated with NAFLD risk through its effects on gut microbiome, inflammation, and dietary emulsifiers that increase intestinal permeability ("leaky gut").

Exercise

Both aerobic exercise and resistance training reduce liver fat, with or without weight loss. Aerobic exercise reduces liver fat by increasing fatty acid oxidation; resistance training improves insulin sensitivity and reduces visceral fat. A combination of both is optimal. Even 150 minutes of moderate exercise per week produces measurable liver fat reduction within 8–12 weeks.

Medical Treatments

GLP-1 Receptor Agonists

Semaglutide (Ozempic, Wegovy) has emerged as one of the most promising pharmacological treatments for NASH. The NASH trial of semaglutide showed that 59% of patients achieved NASH resolution versus 17% on placebo. GLP-1 agonists reduce liver fat through weight loss, improved insulin sensitivity, and direct hepatic effects on lipid metabolism. Explore our medical weight loss programs for more information on GLP-1 therapies.

Vitamin E

Vitamin E (800 IU/day of α-tocopherol) has demonstrated histological improvement in NASH in non-diabetic patients in the PIVENS trial — an effect attributed to its antioxidant properties reducing oxidative stress-driven hepatocyte injury. It is recommended by the AASLD for non-diabetic adults with NASH.

Pioglitazone

A thiazolidinedione (TZD) insulin sensitizer approved for type 2 diabetes that has shown consistent improvement in NASH histology, including fibrosis. Used off-label in non-diabetic NASH patients at some centers; causes weight gain as a side effect.

Resmetirom (Rezdiffra)

In March 2024, the FDA approved resmetirom — the first drug specifically approved for NASH with moderate-to-advanced fibrosis. It selectively activates thyroid hormone receptor beta in the liver, reducing de novo lipogenesis and liver fat content. Approval represents a watershed moment in NAFLD pharmacotherapy.

Monitoring Progress

Repeat liver ultrasound or FibroScan at 6–12 months after initiating lifestyle changes provides objective feedback on liver fat reduction. Liver enzyme normalization is a useful but imperfect surrogate — ALT can normalize even before significant fat reduction. Tracking fasting insulin, HOMA-IR (insulin resistance index), and triglycerides provides insight into the underlying metabolic driver. Connect with a Truventa Medical clinician to develop a comprehensive metabolic health plan personalized to your needs.

References

Younossi ZM, et al. Global epidemiology of nonalcoholic fatty liver disease — Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73-84. PubMed